Paper cutouts of shirts and ties While reduced absenteeism and caregiver burden are important factors for employers, they don’t resonate quite as much with payers. (Photo: Shutterstock)

When assessing the value of a new drug or medical treatment, insurance companies and other payers place a premium on efficacy, safety and cost.

Employers also care about whether adopting an innovation within their health care plan would result in reduced absenteeism and caregiver burden, as well as increased presenteeism and quality of life. However, payers place a low priority on such “indirect benefits,” according to new study published in the Journal of Occupational and Environmental Medicine by researchers at the National Pharmaceutical Council and RTI Health Solutions.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.

More from this author


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.